Mission Wealth Management LP lowered its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 20.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 37,264 shares of the company’s stock after selling 9,597 shares during the quarter. Mission Wealth Management LP’s holdings in AbbVie were worth $8,515,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of the stock. Chelsea Counsel Co. bought a new position in AbbVie in the 3rd quarter valued at $26,000. Westend Capital Management LLC bought a new position in AbbVie in the 4th quarter valued at $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie in the 3rd quarter valued at $31,000. Legacy Wealth Managment LLC ID grew its position in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after acquiring an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC grew its position in AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.
Insider Buying and Selling at AbbVie
In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by corporate insiders.
More AbbVie News
- Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie’s Q1 Results?
- Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably. Article: AbbVie analyst estimate update
- Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?
Wall Street Analysts Forecast Growth
Several equities analysts have commented on ABBV shares. Berenberg Bank set a $275.00 price objective on AbbVie in a research report on Tuesday, January 20th. Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a research report on Thursday, April 30th. Piper Sandler upped their price objective on AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a research report on Thursday. Citigroup cut their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Finally, Canaccord Genuity Group upped their price objective on AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $253.43.
View Our Latest Stock Analysis on ABBV
AbbVie Trading Up 0.1%
Shares of ABBV stock opened at $210.54 on Monday. AbbVie Inc. has a twelve month low of $180.25 and a twelve month high of $244.81. The stock has a market capitalization of $371.97 billion, a price-to-earnings ratio of 103.71, a P/E/G ratio of 0.73 and a beta of 0.32. The stock has a fifty day simple moving average of $210.27 and a two-hundred day simple moving average of $220.05.
AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the prior year, the business earned $2.46 EPS. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. Research analysts predict that AbbVie Inc. will post 14.3 EPS for the current fiscal year.
AbbVie Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date was Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 340.89%.
AbbVie Company Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
See Also
- Five stocks we like better than AbbVie
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
